Objectives: Dengue virus (DENV) infection is a significant risk to over a third of the human population that causes a wide spectrum of illness, ranging from sub-clinical disease to intermediate syndrome of vascular complications called dengue fever complicated (DFC) and severe, dengue hemorrhagic fever (DHF). Methods for discriminating outcomes will impact clinical trials and understanding disease pathophysiology. Study design: We integrated a proteomics discovery pipeline with a heuristics approach to develop a molecular classifier to identify an intermediate phenotype of DENV-3 infectious outcome. Results: 121 differentially expressed proteins were identified in plasma from DHF vs dengue fever (DF), and informative candidates were selected using nonparametric statistics. These were combined with markers that measure complement activation, acute phase response, cellular leak, granulocyte differentiation and viral load. From this, we applied quantitative proteomics to select a 15 member panel of proteins that accurately predicted DF, DHF, and DFC using a random forest classifier. The classifier primarily relied on acute phase (A2M), complement (CFD), platelet counts and cellular leak (TPM4) to produce an 86% accuracy of prediction with an area under the receiver operating curve of >0.9 for DHF and DFC vs DF. Conclusions: Integrating discovery and heuristic approaches to sample distinct pathophysiological processes is a powerful approach in infectious disease. Early detection of intermediate outcomes of DENV-3 will speed clinical trials evaluating vaccines or drug interventions.
Background and objectives
DENV is an arthropod-borne RNA virus that causes significant health and/or economic impact to over 100 dengue-endemic countries in which approximately half of the world's population resides [1] . As a result, dengue fever (DF) is the most common vector-borne viral infection in humans [2] . Symptomatic DENV infections manifest as a flu-like disease characterized by a sudden onset of fever, maculopapular rash, and leucopenia [3] . A small group develop severe dengue disease (SDD), a later-onset syndrome characterized by vascular leakage and/or hemorrhage, leading to 500,000 annual hospitalizations with a case fatality rate of about 5% [4] .
Risk factors for complicated DENV infections are multifactorial; these include host genetic factors [5] [6] [7] [8] [9] [10] , viral strains [11] [12] [13] , anamnestic immune response from previous heterologous exposure [14] [15] [16] , age [17, 18] and/or gender effects [12] . Not surprisingly, then, the clinical manifestations of DENV infection is highly variable in terms of times of onset, involvement of thrombocytopenia [19, 20] , manifestations of endothelial injury/vascular leak [21] , myositis, arthralgias and hepatic involvement [22, 23] . As a result, the World Health Organization (WHO) refined dengue case classification schemes in 2009 to include the identification of non-severe dengue with early warning signs [24] . Accordingly, approaches seeking to discriminate acute, self-limited infections vs those that will progress to SDD have yielded inconsistent results [12, 22, 23, 25] .
Recent advances in global proteomic technologies enable more unbiased methods for disease discrimination than previously possible. Here we report, for the first time, a multi-level strategy for discovery and biomarker qualification of severity of DENV infections in a cohort of DENV-3 infections. This unique cohort represented a valid sampling of the entire infected population, including a balanced mixture of primary and secondary infections [26] . We tested the performance of robust, clinical grade quantitative proteomics measurements that sampled multiple pathophysiological processes, including complement activation, acute phase response, cellular leak, granulocyte differentiation and viral load, on clinical outcome. This study will be of value to produce objective case definition to better evaluate diagnostics and clinical interventions to reduce the impact of DENV-3 infections.
Study design

Study population and case definitions
Patients >5 years of age with suspected DF who were admitted to one of three hospitals in the city of Recife, Pernambuco, Brazil. After written informed consent (or assent) was obtained from each subject (or guardian) clinical and laboratory evaluations were performed on enrollment [33] . Dengue cases were classified according to the 1997 WHO Guidelines. DF was assigned by a high fever accompanied by at least two associated symptoms: headache, retro-orbital pain, myalgia, arthralgia and rash. DHF was defined by the same clinical manifestations as for DF, but with hemorrhagic manifestations, including a positive tourniquet test, thrombocytopenia (<100,000/mm 3 ), hemoconcentration or other sign of plasma leakage [24] . DFC was designated when subjects met the criteria for DF and who presented with hemorrhagic manifestations and thrombocytopenia (<100,000/mm 3 ), but the clinical/laboratory parameters did not fulfill the WHO DHF criteria as described by us earlier [26] . Infectious outcomes were 29.4% DF, 44% complicated DF (DFC), those with hemorrhagic or thrombocytopenia that did not meet the classical WHO criteria, and 8.2% DHF [26] .
Biofluid analysis platform (BAP) fractionation and 2DE
The BAP pre-separation fractionation system is a semiautomated device to fractionate plasma into protein and peptide pools [12] . The protein pools were depleted of the most highly abundant proteins and labeled with BODIPY FL-maleimide (BD) [27, 28] . BD-labeled proteins were separated by 2DE, imaged and analyzed using Progenesis/SameSpots software (Nonlinear Dynamics, Ltd., Newcastle Upon Tyne, UK).
Stable isotope dilution (SID)-selected reaction monitoring (SRM)-MS
Two technical replicates of analysis for each sample were analyzed by SID-SRM-MS. All of the SRM measurements had within-technical replicates coefficient of variation (CV) of 20% or 
Statistical analysis
Statistical comparisons were performed using SPSSv18 (SPSS, Inc., Chicago, IL). 2-way ANOVA, post-hoc testing using Tukey's ttest, and Kruskall-Wallis tests were applied as indicated. Student's t-tests were performed on the 2DE spots. The significance level in all instances was 0.05.
Results
The clinical parameters of the one hundred and ten (1 1 0) study volunteers are shown in Table 1 . The three study groups were matched for age, gender [male/female (M/F)] distribution and days of fever. At the time of presentation, hematocrit (HCT) was significantly different between the DF and DHF diagnoses (p = 0.046, Tukey's t-test). The platelet concentration was also significantly different in all groups (p < 0.001, Tukey's t-test). These data suggested that the DFC was a distinct category of disease.
Discovery of candidate biomarkers related to DENV severity
We first applied discovery proteomics to identify any unique proteins using an unbiased protein profiling strategy (BAP; Methods). In this platform, plasma from a matched set of extremes (29 cases of DF and 22 cases of DHF) were subjected to analysis (Fig. 1) . We detected 1311 protein spots after complete analysis; Student's t-tests were performed on the log 2 -transformed intensities for each. Of these 1311 spots, 121 were significantly different between the two classes (p < 0.05, Table 2 ). The top 10 canonical biological pathways dysregulated by DHF were identified by pathway enrichment analysis. The top 3 pathways included acute phase response signaling, LXR/RXR activation and coagulation system (Fig. 2) . Pathways analysis of the dysregulated network showed an interconnected network enriched in acute phase response proteins, coagulation pathways, and cytoskeletal elements (Fig. 3) . Fig. 1 . Schematic of classification strategy. Schematic view of strategy for identification of disease intermediates associated with DENV disease severity. Extremes of phenotypes were compared for differential expression using BAP pipeline in 51 subjects. Candidate biomarkers were then assembled based on proteins identified in the discovery phase and those that had been identified by previous studies (see Table 3 for further details). For each candidate, targeted proteomics assays using stable isotope dilution (SID)-selected reaction monitoring (SRM) assays were developed, standardized, and used to quantitate the abundance of the candidate biomarker in the entire population (110 patients). Nonparametric random forests classification was then applied to identify informative features of DENV severity.
Candidate panel for disease severity
We subjected the proteins identified in our discovery analysis to statistical feature reduction using a non-parametric method that identifies informative proteins that correlate with clinical phenotype [12, 29, 30] . Three proteins were identified as being most informative: (1) a 250 kDa high molecular weight albumin (HMWAlb) complex; (2) a native alpha 2 macroglobulin (A2M); and (3) a 34 kDa fragment of desmoplakin (DESP); shown in Fig. 4 .
Discriminant markers were combined with a heuristic approach selecting informative protein markers that monitored distinct biological functions known to be dysregulated in DHF Table 3 . These candidates included complement factors -D, -H, and -4A [31] ; acute-phase reactants alpha-1 anti-trypsin (A1AT), fibrinogen ␣/␤ (FIBA/FIBB), ferritin (FRIL) and haptoglobin (HPT); and the granulocyte differentiation marker, leucine rich alpha 2 glycoprotein (AG2L). The immunoglobulins, IgG-1, IgG and IGJ are differentially expressed in DHF, consistent with previous work identifying increased expression of plasmablasts in DHF [31] [32] [33] . The presence of cytoskeletal leak proteins, keratin-1 (KRT1), tropomyosin (TPMH), desmoplakin (DESP), and vimentin (VIME) have been observed in acute DENV infection. Additionally we measured DENV NS1 protein as a surrogate of viral load.
Targeted proteomic assays
Selected reaction monitoring (SRM) was applied as a 'targeted' MS approach for the accurate quantification of predetermined proteins in plasma [34] . For highly informative candidates, such as A2M, the SID-SRM-MS assay shows a LLOQ of 0.064 fmol, and a dynamic range of 10,000 (Supplementary Table 1 ). Complement Factor D (CFD) was measured using an IP-SRM assay. To measure Table 2 ). The horizontal bar for each pathway is its score, calculated as −log10(p), where p is the probability that the specific combination of the implicated proteins occur in the pathway by pure chance. The yellow dots on the bars mark the ratios of the number of pathway proteins in the uploaded data set to the total number of proteins that make up the pathway. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Fig. 3 . Network of interactions. Shown is the top network dysregulated by DHF. The fold changes of protein abundance are marked below the nodes, with a positive value representing up-regulation and a negative value, down-regulation (DHF vs DF). Molecules shown in the network: A2M: alpha-2 macroglobulin; ALB: albumin; APOE: apolipoprotein E; C3: complement component 3; C4A/C4B: complement component 4B; CFB: complement factor B; chymotrypsin; CLU: clusterin; collagen(s); elastase; ERK1/2: map kinase; FGG: fibrinogen gamma chain; fibrinogen; GOT: aspartate aminotransferase; HDL: high-density lipoprotein; hemoglobin; HP: haptoglobin; IgG: immunoglobulin G; IgG1: immunoglobulin G1; IGHG1: immunoglobulin heavy constant gamma 1; IGKC: immunoglobulin kappa constant; kallikrein; KRT9: keratin 9; KRT10: keratin 10; LDL: lowdensity lipoprotein; pro-inflammatory cytokine; SAA4: serum amyloid A4; serine protease; SERPINA1: alpha-1-antitrypsin; SERPINA3: alpha-1-antichymotrypsin; SERPINA5: plasma serine protease inhibitor; SERPINC1: antithrombin-III; stat3: signal transducer and activator of transcription 3; TCF: T cell factor; trypsin. the 34 kDa DESP and 250 kDa HMWAlb fragment, both proteins representing small fractions of the total circulating DESP and Alb respectively, a capillary electrophoresis (CE) pre-fractionation method was developed. Technical replicates indicated that these methods were highly reproducible with <20% CoV Table 3 .
Panel measurement
The circulating levels for the 19 candidate biomarkers were measured in the plasma of 110 study volunteers (59 DF, 29 DFC, 22 DHF) obtained at the time of initial presentation of DENV infection (Fig. 5) . Consistent with our previous studies [12] , the biomarker measurements were not normally distributed and non-parametric statistical methods were used to identify biomarkers that were significantly different between the groups. Of the initial 19 candidates measured, 15 were significantly different (p < 0.05, Kruskal-Wallis test; Supplementary Table 2) . We noted that 8 of these, including dengue NS1, CFD, A1AT, A2M, CO4A, TPM4, FRIL and DESP were significantly different between all three groups. Interestingly, 5 markers, AG2L, KRT1, IGJ, HPT, and VIME were distinct between DFC vs DHF and DF vs DFC, but not between DF vs DHF. These 15 verified biomarkers were then combined with discriminant clinical variables (platelet counts, HCT, and gender) and subjected to nonparametric classification.
Ensemble classification of DENV disease severity
To develop a classifier of DENV severity, we used a random forests classifier, an ensemble classifier that uses many decision tree models to predict outcome [30, 35] . The best model produced 79.7% accuracy for DF (47 of 59 were correctly predicted), 100% accuracy for DFC, and 90.9% accuracy for DHF (20 of 22 were correctly predicted) in 10-fold cross-validation evaluation of model performance (Table 4) . Table 4 Confusion matrix for RF classifier of disease severity. For each disease (class), the prediction success of the RF classifier is shown. 
Post-hoc classifier evaluation
Post-hoc analysis of variable importance was used to identify the features that were most important in the random forest classifier (Fig. 6) . The four most significant variables were A2M, CFD, platelet and TPMH. The ROC of the classifier shows overall model performance in disease classification. From this analysis, the area under the ROC curve (AUC) for DHF prediction is 0.901 (Fig. 7A) . Similarly, the ROC for DFC prediction is 0.945, indicating a high model performance for prediction of intermediate severities of DENV infection (Fig. 7B) .
Discussion
The rapid re-emergence of dengue infections worldwide merits its consideration as an international public health emergency by the WHO [24] . Recent cartographic estimates indicate that the number of acute infections annually may be as high as 400 million [1] . During the acute febrile illness, it is not possible to clinically distinguish self-limited DF from those that will develop complicated DENV infections. Because the early detection of those at risk for SDD will aid in management of disease outbreaks, the identification of those at risk for SDD is of high impact. Here we apply a multivariate strategy in a representative cohort of primary and secondary infections associated with endemic DENV-3 spread [26] to produce more a rigorous, molecular case definition.
Although consensus groups have agreed that dengue represents a single disease entity with different clinical presentations, it is currently controversial as to which criteria can be used to describe the severity of the disease. DENV infection produces a wide spectrum of clinical presentations, with currently an unpredictable disease progression. Following a period of incubation, most patients present with an acute, self-limited, febrile syndrome [1, 3] . A small subgroup will progress to severe disease; currently using clinical case definitions it is not possible to reliably distinguish the two. In response to this difficulty the WHO criteria was modified in 2009 to include the separation of non-severe dengue into those with or without warning signs. However, even patients who present with non-severe dengue can develop DHF or shock, and up to 29% of patients could not be classified suggesting that the current categories will need further refinement [36] .
In our previous characterization of the Recife cohort, we designed a group associated with hemorrhagic complications and thrombocytopenia that did not fulfill the 1997 WHO Guidelines for DHF [24] , yet these manifestations were clearly separate from those with uncomplicated DF. Our studies identify objective criteria that indicate DFC is an intermediate state distinct from DF and DHF. Not only are the platelet counts significantly different between these three groups (Table 1) , but the NS1, CO4A, TPMH, FRIL and DESP biomarkers are as well (Fig. 4) . Together, these findings indicate that DFC is not just an intermediate stage between DF and DHF, but rather may have distinct pathophysiology. More work will be needed to identify subgroups of DENV infection; we contend that addition of objective, molecular criteria may be useful in disease classification.
Plasma is a complex mixture of proteins over a high dynamic concentration range, circulating in protein complexes [37] , and containing alternatively processed protein fragments. The BAP platform deals with many of these difficulties not addressable by conventional "bottom-up" profiling. Denaturation of the plasma prior to its fractionation enables the detection of low abundance biomarkers associated with carrier proteins [38] . Application of saturation fluorescence labeling provides enhanced quantitation over conventional fluorescent dyes in 2DE [27] . Finally, the use of 2DE enables detection of post-translationally modified proteins that would be missed by "bottom-up" approaches. Our discovery of post-translationally modified 250 kDa high molecular weight albumin and the detection of the 34 kDa DESP fragment was possible only by 2DE.
Our BAP discovery proteomics indicate that severe DENV infection dysregulates pathophysiological processes, including the acute phase response, coagulation cascade, and cytoskeletal proteins generated from cytotoxicity; many have been identified previously [12, [39] [40] [41] [42] [43] [44] . The four most informative protein biomarkers identified in this study indicate dysregulation of hepatic acute phase (A2M), the complement alternative pathway (CFD), and cytoskeletal leakage proteins (TPMH), followed by the viral load (NS1). The acute-phase represents a non-specific systemic switch in the hepatic production of plasma proteins to facilitate macrophage opsonization, coagulation and wound repair [45] . A2M is the most informative marker in the DENV classifier, previously identified by 2DE analysis [39] . Our SID-SRM-MS results indicate that A2M is increased in DFC, and is decreased in DHF cases, relative to DF patients (Fig. 3) . This finding suggests that consumption of plasma anti-proteases may play a role in the evolution to DHF. Our finding that CFD is an informative marker is consistent with earlier studies from our group [31] . The expression of CFD in DFC was not examined in this previous study. Additionally, we showed that levels of complement factor B and C3 are reduced on DHF patients [31, 33] . Altogether, our data confirms the role of the alternative pathway of complement system on dengue disease immune-pathogenesis. TPMH is an actin-binding, contractile protein expressed in striated and smooth muscle. Muscle involvement in DENV is documented [46] . Interestingly, DENV NS1 was the fourth most informative biomarker of DENV severity that we identified. NS1 is a highly conserved nonstructural glycoprotein of all flaviruses that is secreted into plasma as a soluble hexameric complex in DENV-infected patients [47] . Previous work has shown that NS1 is responsible for the complement fixing activity in DENV infection [47] forming active SC5b membrane attack complexes on DENV-infected cells in the presence of anti-DENV antibodies [21] , perhaps playing a role in vascular leak. Currently clinical assays rely on enzyme-linked immunosorbent assays for detection of NS1, a detection method that may be unreliable in the presence of anti-NS1 antibodies produced during infection. The SRM assay we have developed would not be sensitive to the interference. Our studies here indicate that NS1 is lower in DHF relative to DF or DFC, perhaps suggesting that DFC may be primarily driven by complement activation, whereas DHF may involve the host inflammatory response.
Our results illustrate the adoption of the targeted SID-SRM-MS assays to provide independent, clinical quality assays for informative protein measurements. SID-SRM-MS is increasingly being accepted for applications in clinical monitoring due to its portability and reproducibility in of assay performance across laboratories and detection platforms [48] . We demonstrate how the SID-SRM-MS assay can be coupled with CE pre-fractionation to detect and quantify informative protein fragments produced from tissue leak (DESP). Moreover, coupling IP enrichment to the SID-SRM-MS assay enables the detection of complement proteins (CFD) at levels comparable to ELISA.
In summary, we report the identification and verification of a nonparametric classifier of severity of DENV infection in an epidemic of DENV-3 infection. Our studies verify 15 markers statistically associated with disease severity, that when combined with platelet counts in the clinical laboratory produce a highly accurate classifier of DENV outcomes. Early detection of intermediate outcomes of DENV will speed clinical trials evaluating clinical vaccine or drug interventions.
Funding
Research support was provided by the NIAID Clinical Proteomics Center, HHSN272200800048C (ARB), National Center for Advancing Translational Science UL1TR000071 UTMB CTSA (ARB), NIEHSP30 ES006676 (ARB) and NIH contract HHSN272201000040I/HHSN27200004/D04 (NV). NIAIDAI56541AI049820, CNPqPRONEX-DENGUE550140/2010-7 -FACEPE project APQ-1516-4.01/10.
